A Phase 1b/2a, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MB-001 in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 04 Feb 2026
At a glance
- Drugs MB 001 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Mage Biologics
Most Recent Events
- 04 Feb 2026 New trial record